Microfluidic Cytometer for Complete Blood Count Analysis, Phase I

RMD proposes to develop a MEMS based complete blood count (CBC) instrument that can be used aboard a spacecraft. We will produce a microfluidic scale combination cell counter-flow cytometer for CBC analyses that can be communicated to ground bases by telemetry. The blood analyzer will utilize innovative optical and fluidic designs on a modular platform that enable compactness, high sensitivity and cell discrimination, combined with robust service. No operator intervention is required. Modules that require direct contact with blood will be economical and disposable. These fluidic designs will be fabricated by microstereolithography and initially tested as two separate components. A first component will constitute a hydrodynamic focusing injector and cell impedance meter. A second component will monitor forward and side scattered light from hydrodynamically focused cells using novel signal collection designs and micrometer scale, Geiger-mode avalanche photodiodes. New, custom formulated photopolymers will be evaluated for microstereolithography use and electroless deposition of metals will form the basis for fabricating microelectrodes. During Phase II, the cell impedance transducer and microoptic modules will be integrated into one credit card size package that plugs into a handheld microelectronics board containing detectors, pump, microprocessors, and an automated cell lysing stage.

This is a mature technology (TRL 7+) — the realistic path in is usually NASA's Technology Transfer Program: licensing an existing NASA patent, or a Space Act Agreement to use NASA facilities/expertise directly. NASA also runs a startup licensing program with no upfront fee for companies formed to commercialize a specific NASA technology.

None of these are guaranteed paths for this specific project — TechPort itself doesn't have an "apply" button. Reaching out to the contact(s) above with a specific question is usually the fastest way to find out what's actually open.